give you the best experience when you visit . by using this website you consent to our use of these cookies . find out more about how we use cookies and how to manage them by reading our cookie notice . close search menu search search search close what science can do what science can do our people our science our science pipeline publications cambridge gothenburg gaithersburg imed biotech unit medimmune global medicines developement our focus areas cardiovascular and metabolic diseases oncology respiratory inflammation and autoimmunity neuroscience infection and vaccines all focus areas all medicines our company our company our strategy leadership team careers careers global careers site investors investor relations results and presentations key facts for investors faqs corporate governance dividend policy regulatory announcements partnering partnering partnering case studies get in touch media media centre image library broadcast videos sustainability sustainability environmental sustainability access to healthcare ethical business practices responsible research great place to work governance more hide az network global site searching for a cure for heart failure read more latest press releases astrazeneca enters agreement with cilag gmbh international to divest rights to rhinocort aqua outside the us 7 october 2016 corporate press release astrazeneca enters agreement with aralez for beta blocker medicine toprol xl in the us 4 october 2016 corporate press release astrazeneca reports top line results from the brilinta euclid trial in patients with peripheral artery disease 4 october 2016 corporate press release featured news can drag and drop cancer simulation speed up drug discovery new drag and drop computer modelling of key signalling pathways in cancer cells may dramatically reduce the need for wet lab experiments to bring truly personalised treatment to patients . drug discovery scientists at astrazeneca are starting to use a cloud based simulation tool biomodel analyzer to bring alive the millions of potential changes in cell signalling that make cancer cells multiply uncontrollably . this ground breaking advance in drug discovery methods is the result of a highly successful collaboration between astrazeneca s imed biotech unit and microsoft . the initial focus of the imed microsoft collaboration has been on a type of blood cancer acute myeloid leukaemia aml . 29 september 2016 liquid biopsy plasma ctdna testing moves into mainstream cancer treatment this week the us food and drug administration approved a cutting edge plasma based test known as a liquid biopsy that can identify non small cell lung cancer nsclc patients with epidermal growth factor receptor egfr t790m mutations . the new test helps break down a significant barrier for lung cancer patients in the us . up to now physicians have relied on a fresh biopsy or tumour tissue sample taken at the time of disease progression to detect resistance mutations such as t790m in the egfr gene and match patients to suitable treatment . the need for non invasive testing is particularly acute when detecting resistance mutations where up to 40 % of patients may find it impossible to donate a tissue sample because tumours are hard to reach or patients are not well enough to undergo biopsy . 29 september 2016 astrazeneca astrazeneca astrazeneca pitchatpalace 6.0 boot camp kicking off with thedukeofyork here at harwellcampus . set to be a great day with som https t.co fsohn8omc6 reply retweet 6 favourite 14 oct 14 astrazeneca astrazeneca we re excited for the pitchatpalace 6.0 bootcamp in oxford tomorrow . congratulations to all the start ups who ve m https t.co k5mcxpykr5 reply retweet 4 favourite 10 oct 13 astrazeneca astrazeneca we are proud to be supporting dukeofyork and pitchatpalace inspiring the next generation of tech entrepreneurs in the uk reply retweet 3 favourite 2 oct 13 follow astrazeneca professor david goldstein to lead astrazeneca s genomics initiative as chief adviser astrazeneca is pleased to announce that professor david goldstein will join the company in the consultative role of chief adviser genomics to lead its integrated genomics initiative which was announced in april . this 10 year initiative will focus on the discovery of new targets and biomarkers linked to molecular mechanisms of disease across astrazeneca s main therapy areas . professor goldstein will continue in his full time role as director of the institute for genomic medicine john e. borne professor and professor of genetics and development at columbia university medical center . he is renowned for his research on human genetic diversity the genetics of disease and pharmacogenetics and will be responsible for driving the scientific progress of astrazeneca s genomics initiative created to transform drug discovery and development across the entire research and development pipeline . 28 september 2016 innovative pancreatic research expands treatment horizons for people with type 2 diabetes new understanding of how hormone producing cells in the pancreas decode their genetic instructions is pointing to novel targets for next generation medicines for type 2 diabetes obesity and other metabolic disorders . a large scale analysis of gene expression in individual islet cells of the pancreas suggests insulin producing beta cells are not the only sub class of cells important for glucose control and diabetes treatment as previously thought . the research carried out at the astrazeneca karolinska insitutet integrated cardiometabolic center icmc stockholm sweden has shown that other types of islet cells notably alpha and delta may also play a significant role . 23 september 2016 peripheral patients pad peripheral arterial disease policy initiative a guest blog post by dr. tony hockley visiting senior fellow department of social policy london school of economics and political science lse . lse is developing a white paper on pad funded by and in collaboration with astrazeneca . pad is a disease that affects around 202 million people worldwide1 and puts a significant strain on health and economic systems yet awareness remains low and sub optimal care is an issue . 19 september 2016 patients at the core of partnership commentary by jennie younger vice president of global corporate affairs on dr. tony hockley s post on pad peripheral arterial disease . 19 september 2016 a game changing scientific collaboration charles river and astrazeneca there are still patients out there with unmet clinical need waiting for new medicines . that s how important this is . astrazeneca and charles river share a passion for ground breaking scientific research . our partnership is focused on accelerating the delivery of new medicines . watch our video to find out more about our success to date . opening up a treasure trove of new drug target opportunities by using novel boronic acid chemistry our scientists have generated covalent inhibitors of mcl 1 a notoriously difficult and key target in oncology . for the first time scientists from our innovative medicines & early development imed biotech unit have shown that it is possible to inhibit high value protein protein interaction ppis drug targets such as mcl 1 through the use of novel lysine targeting covalent warheads . 15 september 2016 join astrazeneca and help us deliver life changing medicines be among our employees who continue to make us an innovation driven company that stands firmly among the world s leaders in biopharmaceuticals . astrazeneca careers partnering the best science doesn t happen in isolation . we partner with others around the world combining the great science in our labs with complementary technologies know how and molecules to accelerate the delivery of new life changing medicines . learn more page atlas id 970733.011 . date of next review april 2017 az network this website is intended for people seeking information on astrazeneca s worldwide business . our country sites can be located in the az nework . website atlas id 917.041.011 date of next review october 2016 resources all resources open innovation externally sponsored scientific research medimmune us prescription assistance programmes global clinical trials information medicines quick links media investor relations partnering careers sustainability social media facebook linkedin twitter legal notice and terms of use privacy notice cookie policy site map contact us astrazeneca 2016 you are now leaving astrazeneca.com you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents . astrazeneca provides this link as a service to website visitors . astrazeneca is not responsible for the privacy policy of any third party websites . we encourage you to read the privacy policy of every website you visit . click cancel to return to astrazeneca s site or continue to proceed . cancel continue important notice for users you are about to access astrazeneca historic archive material . any reference in these archives to astrazeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label efficacy data or safety data . please refer to your approved national product label smpc for current product information . i have read this warning and will not be using any of the contained product information for clinical purposes . i disagree i agree